EUVIMEDEUVIMED entdecken
Crossref

Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy

Yu-Shan Huang iD, Hsin-Yun Sun, Shu-Yuan Ho, Kuan-Yin Lin iD, Wang-Da Liu, Wang-Huei Sheng, Szu-Min Hsieh iD, Yu-Chung Chuang, Li-Hsin Su, Yi-Ching Su, Wen-Chun Liu, Sui-Yuan Chang und 1 weitere

Clinical Infectious Diseases · 04.02.2026 · 81 (6) · 1074-1082

DOI: 10.1093/cid/ciae655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 02.01.2025. Verfasst von Yu-Shan Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Hepatitis D, Coinfection. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir-containing antiretroviral therapy (ART) improves survival in hepatitis B virus (HBV)–coinfected people with HIV (PWH). We investigated the incidence of hepatitis D virus (HDV) infection and its clinical impact in HBV-coinfected PWH in the era of tenofovir-containing ART.

Methods

Between 2011 and 2022, HBV-coinfected PWH were included and followed until December 2023. Anti-HDV antibody screening was performed using sequentially archived blood samples. Timing of incident HDV infection was estimated as the midpoint between the last timepoint of anti–HDV-negative samples and the first timepoint of anti–HDV-positive samples. Differences in survival and liver-related outcomes between HDV-infected and -uninfected PWH were analyzed.

Results

534 HBV-coinfected PWH were included; 36 (6.7%) tested HDV-seropositive at baseline. During 3987.78 person-years of follow-up (PYFU), 50 (10.0%) of 498 anti–HDV-negative PWH seroconverted for HDV, with an overall incidence rate of 12.54 per 1000 PYFU; 88.0% (44/50) of HDV seroconverters were men who have sex with men. After a median follow-up of 10.2 years (84.7% of the follow-up period covered by tenofovir-containing ART), all-cause mortality was 4.7% (25/534). PWH with HDV had significantly higher rates of liver-related mortality (3.5% vs 0.4%, P = .032), cirrhosis (11.3% vs 3.6%, P = .008), and hepatitis flare (28.2% vs 14.2%, P = .001) than HDV-uninfected PWH. In multivariate Cox analysis, HDV infection was associated with liver-related mortality (adjusted HR, 9.696; 95% CI, 1.284–73.222, P = .028). Risk of hepatocellular carcinoma was similar for HDV-infected and HDV-uninfected PWH.

Conclusions

HBV-coinfected PWH remain at risk of HDV superinfection and HDV infection is associated with liver-related death in the era of tenofovir-containing ART.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHIV InfectionsHepatitis DCoinfectionHepatitis BAnti-Retroviral AgentsHumansMaleFemaleIncidenceAdultMiddle AgedHepatitis Delta Virus

Stichwörter der Autor:innen

cirrhosishepatitis B virushepatocellular carcinomainjection drug usesexually transmitted infection

Substanzen

TenofovirAnti-Retroviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.

ORCID-Profile: Yu-Shan Huang, Kuan-Yin Lin, Szu-Min Hsieh, Chien-Ching Hung

Zitieren

APA

Huang, Y. S., Sun, H. Y., Ho, S. Y., Lin, K. Y., Liu, W. D., Sheng, W. H., Hsieh, S. M., Chuang, Y. C., Su, L. H., Su, Y. C., Liu, W. C., Chang, S. Y., & Hung, C. C. (2026). Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy. Clinical Infectious Diseases, 81(6), 1074-1082. https://doi.org/10.1093/cid/ciae655

Vancouver

Huang YS, Sun HY, Ho SY, Lin KY, Liu WD, Sheng WH, et al. Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy. Clinical Infectious Diseases. 2026;81(6):1074-1082. doi:10.1093/cid/ciae655

BibTeX
@article{Huang2026,
  author = {Huang, Yu-Shan and Sun, Hsin-Yun and Ho, Shu-Yuan and Lin, Kuan-Yin and Liu, Wang-Da and Sheng, Wang-Huei and Hsieh, Szu-Min and Chuang, Yu-Chung and Su, Li-Hsin and Su, Yi-Ching and Liu, Wen-Chun and Chang, Sui-Yuan and Hung, Chien-Ching},
  title = {Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {81},
  number = {6},
  pages = {1074--1082},
  doi = {10.1093/cid/ciae655}
}
Kostenlos starten →